Endocrine Abstracts

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is usually recommended. This study sought to evaluate outcomes of surgically treated G3 GEP-NEN patients.Methods: A single-institutional prospective NEN database was reviewed. Patients with G3 GEP-NENs based on World Health Organization (WHO) 2019 definitions included well-differentiated neur...

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The WHO 2017 classification further subdivided G3 NENs into G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Current guidelines favor medical management in most of these patients, and the role of surgical management is not well-defined. We performed a systematic literature review and meta-analysis of surgical management vs ...

MD are the most frequent complaint of women with Cushing Syndrome at the time of diagnosis.Objective: To study the frequency of occurrence of MD in patients with Syndrome Cushing and to characterize their clinical and hormonal parallels. We investigated 34 women (average age of 27 years, variation in age from 18 to 30 years) with a newly identified ACTHA. The patients were divided into 4 groups: (1) the normal cycle is 26–31 days; (2) oligomenorrhea...

We are all aware of the current anxieties over the future of Academic Medicine and Modernising Medical Careers. 10 years ago the BMA cohort of 1995 Medical graduates: Medical Academic Career Intentions was performed. 545 doctors graduating in 1995 were followed up for 10 years. The key findings included: those doctors working in research were doing so to improve future career prospects or as a means to secure a National Training Number (NTN). However being in the transition pe...

Objectives: The aim of the study was to evaluate the normal reference values for thyroid uptake using Technetium-99 m (Tc-99 m) pertechnetate.Methods: Sixty-seven euthyroid patients with primary hyperparathydism who underwent parathyroid imaging with Tc-99 m pertechnetate between January 2012 to April 2014 at the Nuclear Medicine department, Newcastle upon Tyne Hospitals was studied. Electronic medical records and biochemical thyroid functi...

Objectives: The aim of the study was to evaluate the normal reference values for thyroid uptake using Technetium-99 m (Tc-99 m) pertechnetate.Methods: Sixty-seven euthyroid patients with primary hyperparathydism who underwent parathyroid imaging with Tc-99 m pertechnetate between January 2012 to April 2014 at the Nuclear Medicine department, Newcastle upon Tyne Hospitals was studied. Electronic medical records and biochemical thyroid functi...

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

Background: Many patients require IV insulin during their critical illness. Maintenance of insulin in St James’s Hospital ICU is governed by a local protocol. At the time of ICU discharge, IV insulin therapy is often stopped. Transitioning from IV to subcutaneous insulin is often done with endocrinology input. If this is unavailable inappropriate insulin dosing may increase the risk of hypo-/hyperglycaemia.Aims: To reduce the number of episodes of h...

Background: Glutamic acid decarboxylase 65-kilodalton isoform (GAD65) antibody is a known to be present in inhibitory interneurons and pancreatic islet β-cells. Arino et al suggests that high levels of GAD65 present with neurological symptoms should prompt physicians to screen patients for occult cancer. The literature also suggests high GAD65 antibodies have been associated with various malignancies; although large studies are lacking. This research focuses on i...

Paltusotine is a once-daily, oral, selectively-targeted SST2 agonist in development for the treatment of acromegaly. PATHFNDR-1 (NCT04837040) enrolled patients with acromegaly who had an IGF-1 ≤1xULN on a stable (>12 weeks) dose of lanreotide or octreotide. Patients were randomized 1:1 to receive paltusotine 40 mg/day or placebo for 36 weeks. During the first 24 weeks, the paltusotine dose was titrated (range 20-60 mg) based on IGF-1 and tolerance. Dose changes were ...